Clove (Syzygium aromaticum) and its bioactive constituent eugenol alleviate psoriatic inflammation by modulating the
Tin-Yun Ho1,2, Hsin-Yi Lo1, Chiao-Che Chen3
1School of Chinese Medicine & Graduate Institute of Chinese Medicine, China Medical University, Taichung, Taiwan.
Introduction:
Clove (Syzygium aromaticum) is traditionally used for inflammatory skin disorders; however, its specific molecular mechanisms in psoriasis remain poorly defined. This study aimed to evaluate the efficacy of clove extract and its major component, eugenol, and to identify their molecular targets.
Methods:
We used an imiquimod (IMQ)-induced mouse model to assess the effects of oral clove extract and eugenol. Proteomic alterations were identified via isobaric tags for relative and absolute quantitation-based liquid chromatography-tandem mass spectrometry and bioinformatics. The specific interaction with the interleukin-17A (IL-17A)/IL-17 receptor A (IL-17RA) interface was validated through competitive binding assays and molecular docking, with further confirmation via immunohistochemistry.
Results:
Eugenol was identified as the major constituent of clove extract (65.8%). Clove extract and eugenol significantly alleviated psoriasiform lesions, reducing scaling scores and epidermal thickness. Proteomic analysis revealed that both treatments reversed IMQ-induced inflammatory signatures by modulating the interleukin-36 (IL-36) and IL-17 signaling pathways, specifically increasing IL-36 receptor antagonist expression while suppressing IL-36 levels. In vitro assays demonstrated that both treatments inhibited IL-17A-IL-17RA binding in a dose-dependent manner, supported by molecular docking indicating potential interactions between eugenol and IL-17A residues. Immunohistochemical analysis further confirmed reduced nuclear factor-κB (NF-κB) activation, decreased IL-17A expression, and diminished CD11b+ granulocyte infiltration in psoriatic skin.
Conclusion:
Clove extract and its major bioactive constituent eugenol exert significant anti-psoriatic effects through coordinated modulation of the IL-36/IL-17A inflammatory axis and suppression of NF-κB signaling. These findings provide mechanistic insight into the traditional use of clove in inflammatory skin disorders and highlight eugenol as a key bioactive mediator with potential as a complementary therapeutic strategy for psoriasis.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
EPS and iPS Cells in Disease Research
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
The JAK-STAT Signaling Pathway
